
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corporation has demonstrated a notable improvement in its financial performance, highlighted by an operating margin increase of 2,200 basis points year-over-year, reaching (17.3%), surpassing consensus expectations of (21.6%). The company has successfully grown its iDose revenue to approximately $16 million and is projecting a sales contribution of about $115-120 million by 2025, reflecting strong demand for its innovative products. Additionally, Glaukos’ glaucoma revenue reached $84 million, exceeding expectations and showing a remarkable 39% growth, indicating robust market momentum and the potential for substantial revenue expansion through upcoming product launches and a promising pipeline.
Bears say
The analysis of Glaukos Corp reveals a concerning decline in financial performance, particularly with a miss in Corneal Health revenue, which totaled $21 million against a consensus of $22 million, reflecting a growth slowdown from the previous quarter. Additionally, the company's gross margin decreased to 82.3%, slightly below consensus expectations, alongside a relatively high SG&A ratio of 65.0% that may indicate inefficiencies. Management's forecast for flat to declining US iStent franchise revenue amidst rising competition and operational risks raises significant doubts about future growth potential and profitability.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares